Back to results
US 2024/0174740 A1Published application
Multispecific antibodies that target hptp-beta (ve-ptp) and vegf
AssigneeEyePoint Pharmaceuticals, Inc.
InventorKevin PETERS
Life of this patent
Estimating the term…
Abstract
The disclosure provides compositions comprising multi-specific compounds, including a compound that targets a phosphatase and a receptor tyrosine kinase agonist. Also provided are methods for the treatment of conditions associated with angiogenesis, comprising administering a multi-specific compound that targets a phosphatase and a receptor tyrosine kinase agonist.
Claims41
1-98. (canceled)
A method of treating an ocular condition in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of an antibody comprising:
- (a) a first domain that activates Tie2, wherein the first domain comprises an amino acid sequence that is any one of SEQ ID NOs:
- 76-80, an amino acid sequence that is any one of SEQ ID NOs:
- 81-87, an amino acid sequence that is any one of SEQ ID NOs:
- 88-90, an amino acid sequence that is any one of SEQ ID NOs:
- 91-93, an amino acid sequence that is any one of SEQ ID NOs:
- 94-96, and an amino acid sequence that is any one of SEQ ID NOs:
- 97-98;
- and
- (b) a second domain that specifically binds a receptor tyrosine kinase agonist, wherein the second domain comprises an amino acid sequence that is any one of SEQ ID NOs:
- 99-113, an amino acid sequence that is any one of SEQ ID NOs:
- 114-123, an amino acid sequence that is any one of SEQ ID NOs:
- 124-131, an amino acid sequence that is any one of SEQ ID NOs:
- 132-137, an amino acid sequence that is any one of SEQ ID NOs:
- 138-143, and an amino acid sequence that is any one of SEQ ID NOs:
- 144-146.
12 more elements
Dependencies are inferred from the claim text.